Officials could communicate the committee's advice from the meeting, as has happened in the past, and the minister could act accordingly. That could involve accepting the advice, making a decision to ensure patients maintain reimbursed access, as he has prioritised, or both. Probably best to resolve it quickly for patients.
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
If this is an example of a bully playing hardball, it's not the companies
July 21, 2026 - - Latest News -
LTR Pharma secures national US manufacturing and fulfilment partner
July 21, 2026 - - Latest News -
Candidate shows antidepressant signal in difficult to treat depression
July 21, 2026 - - Latest News -
'Our access. Our medicines. Our vaccines. Our medical technology'
July 21, 2026 - - Latest News -
Novartis names Anne Harris to lead Australia and New Zealand
July 20, 2026 - - Latest News -
Why is the system slower than when there was no patient involvement or input?
July 20, 2026 - - Latest News -
No company in its right mind would risk a large private market for this outcome?
July 20, 2026 - - Latest News

